42.37
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - Yahoo Finance
Analyst Expectations For Exelixis's Future - Benzinga
Exelixis (EXEL) Sees Price Target Raised by B of A Securities | EXEL Stock News - GuruFocus
BofA Adjusts Price Target for Exelixis (EXEL) Amid Critical Pipe - GuruFocus
Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (E - GuruFocus
Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis at Jefferies Conference: Strategic Moves for Growth By Investing.com - Investing.com Canada
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - sharewise
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise
Transcript : Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 07 - marketscreener.com
Exelixis Stock Surges 28% YTD: Should You Buy Now Or Sell? - Barchart.com
Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia
Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia
Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Insider Sell: Tomas Heyman Sells Shares of Exelixis Inc (EXEL) - GuruFocus
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? - Yahoo Finance
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business - Yahoo Finance
Product Performance, Big Money Lift Exelixis - Yahoo Finance
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - BioSpace
Exelixis reports promising kidney cancer trial results - Investing.com Australia
Exelixis EVP Haley Patrick J. sells $1.5 million in stock By Investing.com - Investing.com Nigeria
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-0 - GuruFocus
Exelixis EVP Haley Patrick J. sells $1.5 million in stock - Investing.com
Exelixis Executives Engage in Significant Stock Transactions - TradingView
Exelixis reports promising kidney cancer trial results By Investing.com - Investing.com India
Exelixis (EXEL) Reports Promising Results from STELLAR-002 Renal Cancer Trial | EXEL Stock News - GuruFocus
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 | EXEL Stock N - GuruFocus
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June | EXEL Stock News - GuruFocus
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June - New Castle News
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth - Yahoo Finance
Exelixis, Inc.: A Strategic Buy on Positive Momentum - marketscreener.com
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):